Cloud-Clone pushes companion-animal cells into pet-health research

Cloud-Clone says it is expanding the market for companion-animal primary cells with a portfolio aimed at dogs, cats and other species as veterinary drug development and One Health research grow. The move targets a long-running supply gap in animal research tools that has left many labs dependent on fragmented sources or no off-the-shelf options at all.

Why it matters: - Veterinary drug discovery and translational pet-health research are growing, but researchers still lack reliable primary cells from companion animals. - Cloud-Clone is positioning itself to fill that supply gap with standardized cells that support reproducible testing, toxicity work and disease modeling. - The broader market is moving toward precision prevention and targeted therapeutics, which increases demand for living cell models.

What happened: - Cloud-Clone outlined a companion-animal primary-cell portfolio spanning 10 species: dog, cat, pig, sheep, rabbit, guinea pig, chicken, rat, mouse and human. - The company said it offers more than 600 ready-to-use cell products and more than 4,000 stocked cell batches, most of them animal-derived. - The announcement focused on canine and feline cells across the nervous, cardiovascular and musculoskeletal systems. - The release was dated Sept. 14, 2026.

The details: - Cloud-Clone says its cell production is supported by SPF-grade animal facilities and GMP-compliant platforms built over nearly two decades. - The nervous-system lineup includes canine and feline trigeminal ganglion neurons, dorsal-root ganglion neurons, cerebral cortical neurons, cerebral astrocytes and Schwann cells. - The company says it offers more than 90 nervous-system cell types for central and peripheral neuroscience research. - The cardiovascular portfolio includes more than 50 canine and feline primary-cell types, including cardiomyocytes, aortic endothelial cells, smooth-muscle cells, cardiac microvascular endothelial cells and cardiac fibroblasts. - The musculoskeletal lineup includes synoviocytes, articular chondrocytes, skeletal-muscle cells, osteoblasts, tenocytes and nucleus pulposus cells. - Cloud-Clone also supplies primary-cell models for respiratory, digestive, urinary, reproductive, metabolic, ophthalmic and immune tissues, plus mesenchymal stem cells. - Each cell batch ships with a Certificate of Analysis and fluorescence validation images. - The company says its products are available to customers in Europe, North America and the Asia-Pacific region. - The release says Cloud-Clone also maintains social accounts on LinkedIn, Instagram, TikTok and X.

Between the lines: - The release frames companion-animal cells as a strategic alternative to a market dominated by human primary-cell suppliers such as Lonza, Thermo Fisher, Merck, STEMCELL Technologies and PromoCell. - It argues that the lack of off-the-shelf canine and feline cells creates a “species gap” that slows veterinary R&D. - The pitch is also about One Health, with Cloud-Clone tying pet diseases and human diseases to shared mechanisms and cross-species validation. - The company is using portfolio breadth and standardization as its main competitive advantage against a concentrated animal-health industry.

What's next: - Cloud-Clone is betting that demand will rise for targeted therapeutics, precision diagnostics and cell- and gene-therapy candidates in pet health. - The company expects its cell bank to keep serving drug discovery, toxicology and regenerative-medicine work as those markets expand. - Researchers will continue looking for reproducible cell models as they move from broad animal testing toward more species-specific studies.

The bottom line: - Cloud-Clone is making a direct play to become a core supplier for companion-animal research as veterinary medicine and One Health science need better living-cell tools.